Future Targets and New Modalities of Therapy

Co-Chair(s)

• 

  Christine Chen, MD, FRCPC, MEd (she/her/hers)

  Hematologist
  PRINCESS MARGARET CANCER CENTRE
  Toronto, Ontario, Canada
• 

  Joaquin Martínez-López, MD PhD (he/him/his)

  Full Professor/Head of Hematology Department
  H 12 de Octubre/Complutense University
  madrid, Spain

Presentations:

• 10:01 - 10:09 East Coast USA Time

  AbbVie’s etentamig and research pipeline demonstrate a commitment to innovation and functional cure for patients with multiple myeloma
  

  Speaker: Chetasi Talati, MD (she/her/hers) – AbbVie
• 10:09 - 10:17 East Coast USA Time

  CELMoD™ Agents for the Treatment of Multiple Myeloma
  

  Speaker: Michael D. Amatangelo, PhD – Bristol Myers Squibb, Summit, NJ, USA
• 10:17 - 10:25 East Coast USA Time

  New Modalities to Improve Multiple Myeloma Patient Experience and Outcomes
  

  Speaker: Jordan M. Schecter, MD (he/him/his) – Johnson & Johnson Innovative Medicine
• 10:25 - 10:33 East Coast USA Time

  Anitocabtagene Autoleucel: Innovation in BCMA-Targeting Therapeutics
  

  Speaker: Ana Kostic, MD (she/her/hers) – Arcellx, Inc.
• 10:33 - 10:41 East Coast USA Time

  Future Targets and New Modalities of Therapy: ADCs and Epigenetic Regulators in Multiple Myeloma
  

  Speaker: Arun Balakumaran, MD, PhD – Pfizer
• 10:41 - 10:49 East Coast USA Time

  Next-Generation Immunotherapies for Relapsed/Refractory Multiple Myeloma (RRMM): Integrating Costimulatory Bispecific Antibody (bsAb) Signaling
  

  Speaker: Glenn S. Kroog, MD (he/him/his) – Regeneron Pharmaceuticals, Inc